Introduction: We evaluated the clinical profile of the orexin receptor antagonist suvorexant for treating insomnia in patients with mild-to-moderate probable Alzheimer's disease (AD) dementia.
Methods: Randomized, double-blind, 4-week trial of suvorexant 10 mg (could be increased to 20 mg based on clinical response) or placebo in patients who met clinical diagnostic criteria for both probable AD dementia and insomnia. Sleep was assessed by overnight polysomnography in a sleep laboratory. The primary endpoint was change-from-baseline in polysomnography-derived total sleep time (TST) at week 4.
Results: Of 285 participants randomized (suvorexant, N = 142; placebo, N = 143), 277 (97%) completed the trial (suvorexant, N = 136; placebo, N = 141). At week 4, the model-based least squares mean improvement-from-baseline in TST was 73 minutes for suvorexant and 45 minutes for placebo; (difference = 28 minutes [95% confidence interval 11-45], p < 0.01). Somnolence was reported in 4.2% of suvorexant-treated patients and 1.4% of placebo-treated patients.
Discussion: Suvorexant improved TST in patients with probable AD dementia and insomnia.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7984350 | PMC |
| http://dx.doi.org/10.1002/alz.12035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular Signaling Pathways of Quercetin in Alzheimer's Disease: A Promising Arena.
Cell Mol Neurobiol
December 2024
Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511, AlBeheira, Egypt.
Alzheimer's disease (AD) is a neurodegenerative disease characterized by cognitive impairment and memory deficit. Even with extensive research and studies, presently, there is no effective treatment for the management of AD. Besides, most of drugs used in the treatment of AD did not avert the AD neuropathology, and the disease still in a progressive status.
View Article and Find Full Text PDFA fatal familial insomnia patient initially misdiagnosed as Alzheimer's disease: a case report.
BMC Neurol
December 2024
Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, No.264, Guangzhou Road, Gulou District, Nanjing, Jiangsu, 210029, China.
Background: Fatal familial insomnia (FFI) is a rare autosomal dominant inherited disease and a type of prion diseases. We report a case of fatal familial insomnia (FFI) in a 52-year-old man who was initially misdiagnosed as Alzheimer's disease.
Case Presentation: The patient presented with persistent insomnia as the initial symptom, accompanied by cognitive impairment, autonomic dysfunction, and disorders of voluntary movement.
Medication Exposure and Risk of Dementia and Alzheimer's Disease.
Int J Mol Sci
November 2024
Department of Neurology, Seoul National University Bundang Hospital & Seoul National University College of Medicine, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si 13620, Republic of Korea.
Alzheimer's disease (AD), a complex neurodegenerative disease (ND), is the most predominant cause of dementia among the elderly. Generally, elderly people have multiple chronic health conditions, like hypertension, arthritis, diabetes, insomnia, bowel problems, and depression. Although prescribed medications have beneficial therapeutic compositions, some may have side effects that could hinder cognitive function or worsen cognitive decline.
View Article and Find Full Text PDFEvidence for music therapy and music medicine in psychiatry: transdiagnostic meta-review of meta-analyses.
BJPsych Open
December 2024
Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, University of Augsburg, Germany; and DZPG (German Center for Mental Health), University of Augsburg, Germany.
Background: Music therapy is a commonly used intervention added to usual care for psychiatric disorders.
Aims: We review the evidence for music therapy and assess its efficacy as an adjunct therapy across psychiatric disorders.
Method: A systematic literature search was conducted in four scientific databases to identify relevant meta-analyses.
Brain function assessment of acupuncture for chronic insomnia disorder with mild cognitive dysfunction based on fNIRS: protocol for a randomized controlled trial.
Front Neurol
November 2024
Department of Preventive Treatment, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Article Synopsis
- * This study is a randomized controlled trial where participants will receive either manual acupuncture or a placebo over eight weeks, with fNIRS used to assess brain function during cognitive tests.
- * The research aims to reveal how acupuncture impacts sleep quality and mental performance in CID patients with mild cognitive impairment, providing insights into its neurological benefits.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!